- 首页
- Glycogen synthase kinase 3 (GSK-3)
- BRD0705
BRD0705
BRD0705 is a potent, paralog selective and orally active inhibitor of GSK3α (Glycogen synthase kinase 3α) with IC50 of 66 nM and Kd of 4.8 μM. BRD0705 also inhibits GSK3β with IC50 of 515 nM. BRD0705 can be used for acute myeloid leukemia (AML).
此产品仅用于科学研究，我们不为任何个人用途提供产品和服务
-
包装价格促销价数量
-
5mg￥4850.003880.00- +
-
10mg￥8100.006480.00- +
-
50mg￥24037.0019230.00- +
-
100mg￥40612.0032490.00- +
-
200mg￥0.000.00- +
-
500mg￥0.000.00- +
- 货号: ajcx16138
- CAS: 2056261-41-5
- 别名:
- 分子式: C20H23N3O
- 分子量: 321.42
- 纯度: ＞98%
- 溶解度: DMSO: 300 mg/mL (933.36 mM)
- 储存: Store at -20°C
- 库存: 现货
Background
BRD0705 is a potent, paralog selective and orally active inhibitor of GSK3α (Glycogen synthase kinase 3α) with IC50 of 66 nM and Kd of 4.8 μM. BRD0705 also inhibits GSK3β with IC50 of 515 nM. BRD0705 can be used for acute myeloid leukemia (AML).
BRD0705 inhibits kinase function and does not stabilize β-catenin, mitigating potential neoplastic concerns. BRD0705 induces myeloid differentiation and impairs colony formation in AML cells while no effect is observed on normal hematopoietic cells.[1]
BRD0705 impairs leukemia initiation and prolongs survival in AML mouse models.[1]
[1] Florence F Wagner, et al. Sci Transl Med. 2018 Mar 7;10(431):eaam8460.
